Goldline Pharmaceutical Ltd.
Listed
BSE SME
SME
Live Chart
| Category | Subscription | Shares Offered | % of Total | Amount (₹Cr) |
|---|---|---|---|---|
|
Market Maker
|
Awaited |
138,000
|
— | ₹0.59 |
|
QIB
|
Over 1.00x
|
— | — | — |
|
NII / HNI
|
Over 1.00x
|
— | — | — |
|
Retail
|
Over 1.00x
|
— | — | — |
| Total | 1.00x | 138,000 |
100% | ₹0.59 |
| Category | Shares Offered | Amount (₹Cr) | Size (%) |
|---|---|---|---|
| Market Maker | 138,000 | ₹0.59 |
100.00%
|
| Total | 138,000 | ₹0.59 |
100.00%
|
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 6,000 | ₹258,000 |
| Retail (Max — 13 Lots) | 13 | 39,000 | ₹1,677,000 |
| S-HNI (Min — 14 Lots) | 14 | 42,000 | ₹1,806,000 |
| B-HNI (Min — 68 Lots) | 68 | 204,000 | ₹8,772,000 |
Goldline Pharmaceutical Ltd. is proposing an IPO on BSE SME under the SME category. Total issue: 27,00,000 shares (agg. up to ₹12 Cr).
Opens 12 May 2026, closes 14 May 2026. Listing: 19 May 2026. Apply via ASBA or UPI.
| Particulars | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue from Operations | 28.06 | 23.57 | 19.85 |
| EBITDA | 5.83 | 4.30 | 2.19 |
| Profit After Tax (PAT) | 2.83 | 1.81 | 0.26 |
| Net Worth | 10.35 | 7.87 | 5.89 |
| Total Assets | 26.28 | 22.93 | 19.39 |
| Reserves & Surplus | 1.65 | 3.76 | 2.08 |
| Borrowings | 11.03 | 11.13 | 10.83 |
| EBITDA Margin (%) | 20.79 | — | — |
| PAT Margin (%) | 10.10 | — | — |
Goldline Pharmaceutical Ltd. IPO is subscribed 1.00 times by May 14, 2026. Retail: 1.00x. QIB: 1.00x. NII: 1.00x.
| Investor Category | Subscription |
|---|---|
| Qualified Institutional (QIB) | 1.00x |
| Non Institutional (NII/HNI) | 1.00x |
| Retail Individual | 1.00x |
| Total Subscription | 1.00x |
The Goldline Pharmaceutical Ltd. IPO retail category is subscribed 1.00 times as of 14 May 2026. The retail portion is oversubscribed.
Subscribe via your broker app using ASBA or UPI. Opens 12 May 2026 and closes 14 May 2026. Min investment: ₹129,000 (1 lot = 3,000 shares). UPI mandate: 5:00 PM on 14 May 2026.
The Goldline Pharmaceutical Ltd. IPO subscribed 1.00x overall. QIB: 1.00x, NII: 1.00x, Retail: 1.00x. Applications: from NSE/BSE.
Check allotment on the registrar website. Enter your PAN, application number or DP/Client ID. Allotment date: 20 May 2026. Refunds: on 21 May 2026.
The Goldline Pharmaceutical Ltd. IPO listing date is 19 May 2026, Tuesday. Listed on: BSE SME. Issue price: ₹43. Estimated listing: ₹69. GMP: +₹26.
The Goldline Pharmaceutical Ltd. IPO closes on 14 May 2026, Thursday. UPI mandate: 5:00 PM on 14 May 2026. Allotment: 20 May 2026. Listing: 19 May 2026.